# CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

> **NCT00702923** · PHASE1 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 12 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Bicalutamide and CP-675,206 (Tremelimumab)
- **DRUG:** Bicalutamide, CP-675,206 (tremelimumab)
- **DRUG:** Bicalutamide, CP-675,206 (Tremelimumab)
- **DRUG:** Bicalutamide, CP-675,206 (Tremelimumab)
- **DRUG:** Bicalutamide, CP-675,206

## Key facts

- **NCT ID:** NCT00702923
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2011-09
- **Final completion:** 2013-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Enrollment was halted prematurely due to slow accrual.
- **Last updated:** 2019-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702923, "CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00702923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*